Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:China gptkb:classical_Hodgkin_lymphoma hepatocellular carcinoma |
| gptkbp:ATCCode |
L01FF10
|
| gptkbp:brand |
gptkb:AiRuiKa
|
| gptkbp:CASNumber |
1798286-23-4
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:Jiangsu_Hengrui_Medicine
|
| https://www.w3.org/2000/01/rdf-schema#label |
camrelizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
blocks PD-1 receptor
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
immune-related adverse events
reactive cutaneous capillary endothelial proliferation |
| gptkbp:target |
gptkb:PD-1
|
| gptkbp:UNII |
1XU1F2KX1K
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:programmed_cell_death_protein_1_(PD-1)
|
| gptkbp:bfsLayer |
6
|